Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NUVB |
---|---|---|
09:32 ET | 11719 | 3.37 |
09:34 ET | 200 | 3.35 |
09:36 ET | 4336 | 3.33 |
09:38 ET | 9371 | 3.34 |
09:39 ET | 2115 | 3.31 |
09:41 ET | 15856 | 3.275 |
09:43 ET | 1300 | 3.28 |
09:45 ET | 4717 | 3.29 |
09:48 ET | 3106 | 3.3 |
09:50 ET | 100 | 3.3 |
09:52 ET | 2774 | 3.29 |
09:54 ET | 9441 | 3.3 |
09:56 ET | 9928 | 3.29 |
09:57 ET | 400 | 3.29 |
09:59 ET | 100 | 3.3 |
10:01 ET | 16189 | 3.245 |
10:03 ET | 2496 | 3.26 |
10:06 ET | 5585 | 3.26 |
10:08 ET | 9359 | 3.255 |
10:10 ET | 12841 | 3.2308 |
10:12 ET | 700 | 3.24 |
10:14 ET | 6532 | 3.245 |
10:15 ET | 100 | 3.24 |
10:17 ET | 100 | 3.25 |
10:19 ET | 10127 | 3.215 |
10:21 ET | 7590 | 3.215 |
10:24 ET | 600 | 3.205 |
10:26 ET | 4306 | 3.215 |
10:28 ET | 2199 | 3.215 |
10:30 ET | 300 | 3.215 |
10:32 ET | 542 | 3.214 |
10:33 ET | 1331 | 3.22 |
10:35 ET | 200 | 3.225 |
10:37 ET | 500 | 3.22 |
10:39 ET | 600 | 3.225 |
10:42 ET | 825 | 3.23 |
10:44 ET | 200 | 3.22 |
10:46 ET | 493 | 3.22 |
10:50 ET | 2053 | 3.22 |
10:51 ET | 334 | 3.235 |
10:53 ET | 2373 | 3.23 |
10:55 ET | 286 | 3.235 |
11:00 ET | 1400 | 3.235 |
11:02 ET | 600 | 3.2312 |
11:04 ET | 400 | 3.235 |
11:06 ET | 12686 | 3.225 |
11:08 ET | 4470 | 3.225 |
11:09 ET | 10750 | 3.245 |
11:11 ET | 1605 | 3.25 |
11:13 ET | 2078 | 3.255 |
11:15 ET | 400 | 3.25 |
11:18 ET | 5211 | 3.245 |
11:20 ET | 300 | 3.245 |
11:22 ET | 600 | 3.245 |
11:24 ET | 958 | 3.25 |
11:26 ET | 600 | 3.245 |
11:27 ET | 500 | 3.245 |
11:29 ET | 500 | 3.245 |
11:31 ET | 650 | 3.245 |
11:33 ET | 1200 | 3.245 |
11:36 ET | 1600 | 3.245 |
11:38 ET | 2960 | 3.234 |
11:40 ET | 1100 | 3.235 |
11:42 ET | 700 | 3.235 |
11:44 ET | 200 | 3.235 |
11:45 ET | 15740 | 3.255 |
11:47 ET | 4119 | 3.255 |
11:49 ET | 100 | 3.26 |
11:54 ET | 1000 | 3.2599 |
11:56 ET | 5481 | 3.245 |
11:58 ET | 2626 | 3.24 |
12:00 ET | 27035 | 3.235 |
12:02 ET | 7211 | 3.215 |
12:03 ET | 4325 | 3.22 |
12:05 ET | 3176 | 3.215 |
12:07 ET | 3280 | 3.22 |
12:09 ET | 400 | 3.215 |
12:12 ET | 2535 | 3.215 |
12:14 ET | 1638 | 3.215 |
12:16 ET | 4465 | 3.225 |
12:18 ET | 1402 | 3.22 |
12:20 ET | 200 | 3.215 |
12:21 ET | 100 | 3.215 |
12:23 ET | 1596 | 3.215 |
12:25 ET | 1981 | 3.2099 |
12:27 ET | 2604 | 3.2 |
12:30 ET | 22628 | 3.225 |
12:32 ET | 1804 | 3.215 |
12:34 ET | 914 | 3.22 |
12:36 ET | 3438 | 3.215 |
12:38 ET | 238 | 3.215 |
12:39 ET | 7733 | 3.22 |
12:41 ET | 532 | 3.215 |
12:43 ET | 3493 | 3.22 |
12:45 ET | 100 | 3.23 |
12:48 ET | 2500 | 3.2285 |
12:50 ET | 2201 | 3.23 |
12:52 ET | 1660 | 3.225 |
12:54 ET | 200 | 3.22 |
12:56 ET | 506 | 3.225 |
12:57 ET | 4389 | 3.215 |
12:59 ET | 6125 | 3.22 |
01:01 ET | 1100 | 3.22 |
01:03 ET | 300 | 3.215 |
01:08 ET | 631 | 3.22 |
01:10 ET | 600 | 3.215 |
01:12 ET | 1100 | 3.2199 |
01:15 ET | 100 | 3.215 |
01:17 ET | 1659 | 3.215 |
01:19 ET | 200 | 3.215 |
01:24 ET | 800 | 3.215 |
01:26 ET | 2851 | 3.215 |
01:30 ET | 2332 | 3.215 |
01:32 ET | 833 | 3.215 |
01:33 ET | 100 | 3.215 |
01:35 ET | 600 | 3.22 |
01:37 ET | 633 | 3.215 |
01:39 ET | 100 | 3.215 |
01:42 ET | 758 | 3.215 |
01:44 ET | 229 | 3.215 |
01:46 ET | 200 | 3.215 |
01:48 ET | 222 | 3.215 |
01:50 ET | 1430 | 3.215 |
01:51 ET | 820 | 3.215 |
01:53 ET | 944 | 3.215 |
01:55 ET | 1600 | 3.215 |
01:57 ET | 1047 | 3.215 |
02:00 ET | 1760 | 3.215 |
02:02 ET | 2361 | 3.215 |
02:04 ET | 100 | 3.215 |
02:06 ET | 731 | 3.215 |
02:08 ET | 100 | 3.215 |
02:09 ET | 504 | 3.215 |
02:11 ET | 555 | 3.215 |
02:13 ET | 621 | 3.215 |
02:15 ET | 300 | 3.22 |
02:18 ET | 569 | 3.215 |
02:20 ET | 100 | 3.215 |
02:22 ET | 221 | 3.215 |
02:24 ET | 200 | 3.215 |
02:26 ET | 601 | 3.215 |
02:27 ET | 630 | 3.215 |
02:29 ET | 421 | 3.215 |
02:31 ET | 1634 | 3.215 |
02:33 ET | 1093 | 3.215 |
02:36 ET | 1037 | 3.215 |
02:38 ET | 742 | 3.215 |
02:40 ET | 920 | 3.215 |
02:42 ET | 997 | 3.215 |
02:44 ET | 718 | 3.215 |
02:45 ET | 24876 | 3.214 |
02:47 ET | 18362 | 3.22 |
02:49 ET | 2544 | 3.211 |
02:56 ET | 549 | 3.215 |
02:58 ET | 1145 | 3.215 |
03:00 ET | 604 | 3.215 |
03:02 ET | 904 | 3.215 |
03:03 ET | 700 | 3.215 |
03:05 ET | 1072 | 3.215 |
03:07 ET | 1504 | 3.215 |
03:09 ET | 654 | 3.215 |
03:12 ET | 1004 | 3.215 |
03:14 ET | 200 | 3.215 |
03:16 ET | 1436 | 3.215 |
03:18 ET | 500 | 3.215 |
03:20 ET | 711 | 3.21 |
03:21 ET | 942 | 3.215 |
03:23 ET | 200 | 3.22 |
03:25 ET | 300 | 3.215 |
03:27 ET | 568 | 3.215 |
03:30 ET | 2200 | 3.215 |
03:32 ET | 6117 | 3.225 |
03:34 ET | 10619 | 3.25 |
03:36 ET | 651 | 3.245 |
03:38 ET | 330 | 3.245 |
03:39 ET | 456 | 3.245 |
03:41 ET | 1500 | 3.245 |
03:43 ET | 879 | 3.245 |
03:45 ET | 1169 | 3.245 |
03:48 ET | 9714 | 3.225 |
03:50 ET | 1064 | 3.22 |
03:52 ET | 2275 | 3.225 |
03:54 ET | 1955 | 3.225 |
03:56 ET | 4544 | 3.225 |
03:57 ET | 21781 | 3.225 |
03:59 ET | 41172 | 3.25 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nuvation Bio Inc | 801.8M | -9.4x | --- |
Longboard Pharmaceuticals Inc | 782.3M | -8.9x | --- |
ALX Oncology Holdings Inc | 844.5M | -4.3x | --- |
ARS Pharmaceuticals Inc | 846.9M | -15.3x | --- |
Praxis Precision Medicines Inc | 834.5M | -2.1x | --- |
Mesoblast Ltd | 804.9M | -5.1x | --- |
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $801.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 246.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.44 |
EPS | $-0.35 |
Book Value | $2.76 |
P/E Ratio | -9.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.